Distribution of Neuroendocrine Cells in the Transition Zone of the Prostate
Table 1
Baseline characteristics of the 3 groups of patients with prostate cancer.
Characteristics/group
A
B
C
value
Patients ()
22
23
35
Age (years)
0.044
Median
64
63
68
Range
54–75
50–74
54–75
PSA (ng/ml)
0.205
Median
5.9
5.7
6.8
Range
3.5–19.8
4.1–10.7
4.1–21.8
Maximum cancer diameter (mm)
0.016
Median
16
12
11
Range
2–28
2–24
3–30
Pathological Gleason sum [ (%)]
0.299
6
1 (4.5)
2 (8.7)
7 (20.0)
7
12 (54.5)
16 (69.6)
22 (62.9)
8
8 (36.3)
3 (13.0)
2 (5.7)
9
5 (22.7)
2 (8.7)
4 (11.4)
Pathological stage (%)
0.938
pT2a
11 (50.0)
14 (60.9)
23 (65.7)
pT2b
3 (13.6)
2 (8.7)
3 (8.6)
pT2c
6 (27.3)
6 (26.1)
7 (20.0)
pT3a
1 (4.5)
1 (4.3)
1 (2.9)
pT3b
1 (4.5)
0 (0)
1 (2.9)
Estimated prostate volume (ml)
<0.001
Median
23.1
29.4
48.6
Range
15.5–35.8
17.0–47.8
29.1–106.0
Estimated transition zone volume (ml)
<0.001
Median
—
10.1
23.3
Range
—
3.9–17.0
12.5–57.0
Group A had no adenomatous nodule, group B had small nodules, and group C had large nodules in the prostatic transition zone in pathological findings. Kruskal-Wallis test. Chi-square test.
